NCT00080483View on ClinicalTrials.gov

Testosterone and Growth Hormone for Bone Loss in Men

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
HypopituitarismHypogonadismGrowth Hormone Deficiency
Interventions
DRUG

Testosterone plus somatropin

AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years

DRUG

testosterone

AndroGel transdermally 5 g a day for two years

Trial Locations (1)

19104

Hospital of the University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

University of Pennsylvania

OTHER

NCT00080483 - Testosterone and Growth Hormone for Bone Loss in Men | Biotech Hunter | Biotech Hunter